Efficacy and Safety of Aflibercept 8 mg in PHOTON Trial in DMO


Dr. Marion Munk examines the Phase 2/3 clinical trial of high-dose aflibercept (8 mg) in diabetic macular oedema, presenting key outcomes and clinical implications of the data.

Related Videos
Marion Munk, MD, PhD, presenting slides
© 2024 MJH Life Sciences

All rights reserved.